Marshall Fordyce - Aug 28, 2024 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Aug 28, 2024
Transactions value $
-$1,071,877
Form type
4
Date filed
8/30/2024, 04:04 PM
Previous filing
Aug 23, 2024
Next filing
Sep 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $43.2K +14.9K +4.63% $2.90 338K Aug 28, 2024 Direct
transaction VERA Class A Common Stock Sale -$549K -14.9K -4.42% $36.80 323K Aug 28, 2024 Direct F1, F2
transaction VERA Class A Common Stock Options Exercise $2.03K +700 +0.22% $2.90 323K Aug 28, 2024 Direct
transaction VERA Class A Common Stock Sale -$26.3K -700 -0.22% $37.54 323K Aug 28, 2024 Direct F1, F3
transaction VERA Class A Common Stock Sale -$515K -14K -4.34% $36.82 309K Aug 28, 2024 Direct F1, F4
transaction VERA Class A Common Stock Sale -$26.3K -700 -0.23% $37.53 308K Aug 28, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -15.6K -1.82% $0.00 843K Aug 28, 2024 Class A Common Stock 15.6K $2.90 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
F2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.59, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.44, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.61, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F6 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.